|

PF-06821497 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Mevrometostat

Pipeline

Phase 3: 2

Top Sponsors

  • Pfizer2

Indications

  • Cancer2
  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)1
  • Metastatic Castration-resistant Prostate Cancer1

Homewood, Alabama1 trial

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Urology Centers of Alabama

Phase 3

Chandler, Arizona1 trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Ironwood Cancer & Research Centers

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.